NeuroOne Approves 10,000-Share Option at $0.802 Exercise Price
NeuroOne’s independent directors approved on April 1 a 10,000-share stock option grant at a $0.802 exercise price under its 2021 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4). The option carries a ten-year term and vests 25% after one year and quarterly thereafter over three additional years.
1. Independent Directors Approve Inducement Grant
On April 1, 2026, NeuroOne’s independent directors approved an equity award under the company’s 2021 Inducement Plan as a material inducement for a new hire, satisfying Nasdaq Listing Rule 5635(c)(4) requirements.
2. Option Award Terms
The new employee received an option to purchase 10,000 shares of common stock at an exercise price of $0.802 per share, matching the closing price on the grant date, with a ten-year term.
3. Vesting Schedule
The option vests over four years, with 25% vesting on April 1, 2027 and the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to continued employment and acceleration or forfeiture provisions.
4. Company Overview
NeuroOne develops high-definition, minimally invasive electrode platforms with four FDA-cleared product families and is advancing research in drug delivery and spinal cord stimulation to improve neurological surgical outcomes.